

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

“TRASTUZUMAB INJECTION” APPROVED FOR LAUNCH TO MARKET

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announced that the biosimilar drug “Trastuzumab Injection” (Saituo (賽妥)) developed by the Group has obtained a drug registration certificate from the National Medical Products Administration of China, approved for the treatment of HER2 (human epidermal growth factor receptor 2) positive early breast cancer, metastatic breast cancer and metastatic gastric cancer.

Saituo (trastuzumab injection) was developed in strict compliance with the technical guidelines for the development and evaluation of biosimilar drugs in China. Its specification is 150mg/bottle, which is ready-to-use and leaves no remaining portion. This not only reduces the workload of clinical medical staff, but also avoids the risks caused by improper storage of the medicine. Moreover, there is no need to add benzyl alcohol as a preservative in the small-dose packaging to ensure the stability of the drug, reducing the risk of poor therapeutic effect due to changes in the protein structure of the drug during clinical treatment, and helping patients reduce hemolysis, dizziness, headache, nausea and vomiting and other adverse reactions⁽¹⁾, to achieve long-term high-quality survival of patients, and to benefit more patients and families.

Breast cancer is the number one malignant tumor threatening women’s health around the world. In 2020, nearly 420,000 breast cancer cases were diagnosed in China. Among them, HER2-positive breast cancer accounted for about 15%-20% of all breast cancer cases. The tumor cells are more malignant, the disease progresses faster, and they are more prone to metastasis and recurrence⁽²⁾. The approval of Saituo (trastuzumab injection) provides a new treatment option for patients with HER2-positive breast and gastric cancer.

With regard to breast cancer and other therapeutic fields with high clinical needs, the Group has focused on the future and proactively launched a wide range of deployments. For HER2-positive breast cancer patients, in addition to the successful launch of trastuzumab, the Group is also planning to launch a biosimilar drug of pertuzumab, forming a “trastuzumab-pertuzumab combination”. In addition, the Group continues to develop a variety of new drugs, including bispecific antibodies and bispecific ADC (antibody-drug conjugate) drugs, and further expands the treatment population to groups with low HER2 expression, providing cancer patients with more and better treatment options.

References:

1. *Le Basle Y, et al. J Pharm Sci 2020; 109(1): 169-190.*
2. *Gion M, Trapani D, Cortés A, et al. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. Am Soc Clin Oncol Educ Book. 2022 Apr; 42: 1-11.*

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 27 July 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.